Pharmaceuticals
ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies
SAN FRANCISCO, Feb. 8, 2023 /PRNewswire/ -- ReviR Therapeutics, a privately held developer of a suite of small molecule RNA-targeting technologies for cancer and other genetically-defined diseases, and Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing, an...
2023-02-08 22:00
1825
Meihua International Medical Technologies Co. Explores Application of ChatGPT Technologies to Develop Online AI Health Consultation Services
YANGZHOU, China, Feb. 8, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the Company will...
2023-02-08 20:30
1457
A Joint Collaboration Between Bio Immunitas and GenScript ProBio Leads to the Development and Fast Track Manufacturing of A Novel Therapeutic Platform
NANJING, China, Feb. 8, 2023 /PRNewswire/ -- GenScript ProBio, a leading Biologics CDMO to the bio-pharmaceutical market, and Bio Immunitas, a UK pharmaceutical company with a novel, safe and efficacious human Recombinant Protein Platform (hRPP), announced their partnership to enhance an already ...
2023-02-08 17:00
1662
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointedRegis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, ...
2023-02-08 16:05
1971
ATMA OFFERS PSYCHEDELIC-ASSISTED THERAPY TRAINING IN AUSTRALIA TO SUPPORT PSYCHIATRISTS AND HEALTHCARE PROFESSIONALS
In response to Australia's approval of MDMA and psilocybin use in therapy AUSTRALIA, Feb. 7, 2023 /PRNewswire/ -- ATMA Journey Centers Inc. ("ATMA"), Canada's leading psychedelic-assisted therapy training provider, is pleased to offer its psychedelic therapy training programs toAustralia's psych...
2023-02-08 01:00
2295
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 7, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics today announced ...
2023-02-07 16:34
2664
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's i...
2023-02-07 06:30
1824
Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis
First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced the Therapeutic Goods Administration (TGA) i...
2023-02-07 06:00
3176
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
WILMINGTON, Del., Feb. 6, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's inves...
2023-02-06 21:10
1644
Pierre Fabre pursues its commitment against rare diseases in the pediatric, oncology and dermatology fields.
RARE DISEASE DAY – February 28th, 2023 The diseases are rare, but they impact a lot of people : nearly 300 million people are affected worldwide1. CASTRES, France, Feb. 6, 2023 /PRNewswire/ -- International Rare Disease Day® will be held onFebruary 28, an opportunity for the Pierre Fabre Group t...
2023-02-06 18:00
1906
Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb
SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announced that the U.S. Food and Drug Administration (FDA) recently granted the initial investigational new drug (IND) application for its drug candidate IMG-008, a long-acting anti-IL-36R antib...
2023-02-06 18:00
1864
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
* Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstratesclinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; * Clinically meaningful improvements were reported in CRISS (the key compos...
2023-02-06 13:01
1739
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks - Development of treatment for pulmonary fibrosis which is unsatisfactory and in high demand, and anticipation for extended adaptability against various rare fibrosis diseases SEOUL, South Korea, Fe...
2023-02-06 13:00
1560
Boehringer Ingelheim Philippines is awarded Top Employer for the 5th year in a row
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition M...
2023-02-06 08:00
1975
Qiming Venture Partners Backed Structure Therapeutics Successfully Debuts on Nasdaq
SHANGHAI, Feb. 4, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued a...
2023-02-04 14:45
7142
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointedRoger Sidhu, M.D., as Chief Medical Officer. Dr. Sidhu is a seasoned lea...
2023-02-03 22:00
4505
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based inSouth Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, ...
2023-02-03 14:34
2488
Briggs wins "National Manufacturing Award 2022" at Make UK, UK's leading Manufacturer's Organization
HONG KONG, Feb. 2, 2023 /PRNewswire/ -- CIMC Enric Holdings Limited ("CIMC Enric")and its subsidiaries (collectively, the "Company") (Hong Kong stock code: 3899.HK) are pleased to announce that, Briggs of Burton PLC ("Briggs"), a subsidiary of CIMC Enric's liquid food business, has been awarded t...
2023-02-03 13:54
3086
Servier full year 2021/22 results confirm the transformation trajectory of the Group
* Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales * Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, up 2.0% (stable at CERi) * Important development...
2023-02-02 14:30
2034
SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan
TOKYO, Feb. 2, 2023 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused Ultrasound (HIFU)...
2023-02-02 14:00
1602
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
8263
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
6458
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6406
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
6176
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6139
